{
    "ticker": "OKYO",
    "name": "OKYO Pharma Limited",
    "description": "OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of inflammatory and pain conditions. Founded in 2015 and headquartered in London, UK, OKYO is committed to advancing new treatments for unmet medical needs, particularly in the fields of ophthalmology and inflammatory diseases. The company's lead product candidate, OK-101, is an innovative therapeutic agent designed to treat dry eye disease, a common and debilitating condition that affects millions of people worldwide. By leveraging its proprietary drug delivery technologies and a robust pipeline of product candidates, OKYO Pharma aims to improve patient outcomes and quality of life. The company utilizes a combination of scientific expertise and strategic collaborations to advance its drug development programs, and it is actively engaged in preclinical and clinical studies to validate its innovative approaches. OKYO is dedicated to addressing the challenges patients face in managing chronic inflammatory conditions and aims to bring forward a new generation of therapies that are both effective and well-tolerated. Through its commitment to research and development, as well as its focus on patient-centered solutions, OKYO Pharma is poised to make a significant impact in the biopharmaceutical landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "London, United Kingdom",
    "founded": "2015",
    "website": "https://www.okyopharma.com",
    "ceo": "Michael Redman",
    "social_media": {
        "twitter": "https://twitter.com/OKYOPharma",
        "linkedin": "https://www.linkedin.com/company/okyopharma/"
    },
    "investor_relations": "https://www.okyopharma.com/investors",
    "key_executives": [
        {
            "name": "Michael Redman",
            "position": "CEO"
        },
        {
            "name": "David W. C. Evans",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "OK-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "OKYO Pharma Limited | Innovative Therapies for Inflammatory Conditions",
        "meta_description": "Explore OKYO Pharma Limited, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for inflammatory and pain conditions, including dry eye disease.",
        "keywords": [
            "OKYO Pharma",
            "Biopharmaceuticals",
            "Inflammatory Diseases",
            "Dry Eye Disease",
            "OK-101"
        ]
    },
    "faq": [
        {
            "question": "What does OKYO Pharma specialize in?",
            "answer": "OKYO Pharma specializes in developing innovative therapies for inflammatory and pain conditions."
        },
        {
            "question": "What is OK-101?",
            "answer": "OK-101 is OKYO Pharma's lead product candidate designed to treat dry eye disease."
        },
        {
            "question": "When was OKYO Pharma founded?",
            "answer": "OKYO Pharma was founded in 2015."
        },
        {
            "question": "Where is OKYO Pharma headquartered?",
            "answer": "OKYO Pharma is headquartered in London, United Kingdom."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "SNY",
        "VRTX"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "ABBV",
        "GILD"
    ]
}